ENZYME KEEPS BREAD FRESH LONGERNovo Nordisk BioIndustrials Inc. of Danbury, Conn., said itsanti-staling enzyme Novamyl has been very successful in testsconducted by the American Institute of Baking, ingredientcompanies and bakeries. Novamyl, first sold in late 1990, is anatural enzyme produced by fermentation, said Novo spokesmanScott Clark.

Novamyl, a carbohydrase enzyme, increases the moisturecontent of bread by modifying bread's starch molecules.Novamyl is better than Novo's earlier anti-staling enzymeCeramyl because Novamyl is a single carbohydrase enzyme,whereas Ceramyl was a blend of enzymes, said Clark.Contaminants in the Ceramyl preparation caused bread to begummy at high enzyme concentrations.

Novo developed Ceramyl and Novamyl to provide naturalalternatives for bakers who were using synthetic chemicals toslow the staling of bread. More than 10 percent of the 6 billionloaves of white bread produced in the United States each yearare thrown away because they become stale, said Clark. --Carol Talkington Verser, Ph.D.

INVESTORS BUY APPLIED DNA STOCK

Applied DNA Systems Inc. has sold 4 million shares of commonstock (NASDAQ:ADNAE) to a group of private investors for$280,000. The investors, led by Edmund Stein and MiloKleinberg, have an option to buy 3 million more shares for thesame 7 cents-per-share price.

Stein and Kleinberg joined the board, and five directorsresigned. The new investors have the right to name threeadditional members to the seven-member board.

Applied DNA sells a 10-day in vitro chemosensitivity assay.The assay is used with tumor biopsies to determine whethertumor tissue is resistant or sensitive to chemotherapy drugs.

Applied DNA stock has traded in the range of 10 cents to 35cents for the past three months, said Alain Klapholz, chieffinancial officer at the Warwick, R.I., company. The companylost about $1 million in 1990 on revenues of about $700,000,he said.

BIOTECHNICA BEGINS CORN FIELD TRIALS

BioTechnica International Inc. (NASDAQ:BIOT) of Minnetonka,Minn., has begun small-scale field trials in four Midwesternstates of genetically engineered corn plants containing a genefor improved nutritional quality. The gene to be tested is oneof three amino acids -- lysine, methionine and tryptophan --for enhanced nutritional value in commodity corn used forswine and poultry. Almost two-thirds of the yearly U.S.production of 8 billion bushels of corn is fed to animals. Cornfor feed use is valued at more than $10 billion at the animalfeeder level.

MARROW-TECH GETS APPROVAL TO TEST DERMAGRAFT

Marrow-Tech Inc. on Monday said it has receivedinvestigational device exemption approval from the Food andDrug Administration to begin clinical trials of its Dermagraftliving skin replacement product in patients with chronicvenous skin ulcers. More than 600,000 people in the UnitedStates suffer from the disorder, which is related to abnormalcirculation in leg veins. La Jolla, Calif.-based Marrow-Tech(NASDAQ:MAROA) in January began testing Dermagraft inpatients with severe burns.

(c) 1997 American Health Consultants. All rights reserved.